Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
70.65(c) 68.93(c) 68.93(c) 69.67(c) 69.56(c) Last
8 902 529 15 465 600 8 518 463 9 411 737 7 724 167 Volume
+0.54% -2.43% 0.00% +1.07% -0.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 26 515 M - -
Net income 2021 7 187 M - -
Net Debt 2021 22 390 M - -
P/E ratio 2021 12,1x
Yield 2021 4,07%
Sales 2022 24 071 M - -
Net income 2022 6 360 M - -
Net Debt 2022 17 055 M - -
P/E ratio 2022 13,9x
Yield 2022 4,28%
Capitalization 87 255 M 87 255 M -
EV / Sales 2021 4,14x
EV / Sales 2022 4,33x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
Sector
Biotechnology & Medical Research
Calendar
12/07 | 08:00amPresentation
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GILEAD SCIENCES, INC.
12/04Gilead recalls vials of COVID-19 drug remdesivir due to glass contamination
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02DOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading
DJ
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/01GILEAD SCIENCES : Statement on Veklury« (Remdesivir) and the SARS-CoV-2 Omicron Variant
PU
11/30NRX Pharmaceuticals Shares Slide 16% After Soaring on COVID-19 Drug, Vaccine Updates
MT
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Regeneron's COVID-19 antibody drug may be less effective against Omicron
RE
11/30Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
AQ
11/29NRX Pharmaceuticals Soars After Saying Zyesami Outperformed Remdesivir for Critical COV..
MT
11/29Gilead Sciences Selects Amazon Web Services as Cloud Provider
MT
11/29Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
BU
11/24Gilead Sciences' Trodelvy (sacituzumab govitecan) Granted European Commission Marketing..
AQ
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
11/23Gilead Sciences' Trodelvy Gets Marketing Authorization from European Commission
MT
More news
News in other languages on GILEAD SCIENCES, INC.
12/03INTESA SANPAOLO : premia migliore startup innovativa a Pni 2021
12/02STARTUP : 16 i progetti finalisti per Pni 2021
11/30Les actions de NRX Pharmaceuticals chutent de 16% après avoir grimpé en flèche grâce au..
11/30Selon Oppenheimer, les noms pharmaceutiques connaîtront une volatilité accrue en fin d'..
11/29NRX Pharmaceuticals s'envole après avoir déclaré que le Zyesami a surpassé le Remdesivi..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 69,56 $
Average target price 75,95 $
Spread / Average Target 9,19%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819
BEIGENE, LTD.36.22%32 284